Informed Prostate Cancer Patient Support

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study - The Lancet Summary Background Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management. Methods In this multicentre, two-arm, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant met

Xofigo 2.0 | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Xofigo 2.0 13-16 minutes Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. Radium 223 emits powerful alpha radiation that kills the cancer cells in the bone metastases. It has been found to double 2-year survival (see this link ), extending survival time and reducing skeletal-related events by almost a third . It often will not reduce PSA or show bone metastases shrinking in imaging, which some patients find disappointing. It is FDA-approved for treatment of castration-resistant men with painful bone metastases, who do not show evidence of visceral metastases on a CT or MRI scan (lymph node metastases are allowed). So far, it is onl

Update on Osteoporosis — What You Should Know About Dietary Recommendations and the Latest Therapeutics | Cooking with Kathy Man cookwithkathy.wordpress.com Update on Osteoporosis — What You Should Know About Dietary Recommendations and the Latest Therapeutics 14-17 minutes Densie Webb wrote . . . . . . . . . In the midst of a pandemic, it’s easy for clients to forget about other pressing medical conditions they urgently need to focus on for prevention or treatment. These may include osteoporosis and low bone mass, which, according to the National Osteoporosis Foundation (NOF), affect about 54 million Americans. Of those, an estimated 10 million have osteoporosis, and 34 million people have low bone mass, putting them at future risk of osteoporosis. To further emphasize the gravity of the disease, the NOF points to studies suggesting that approximately 1 in 2 women and up to 1

Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer | MedPage Today medpagetoday.com Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer Follow 7-9 minutes Oncology/Hematology > Prostate Cancer — Results comparable to enzalutamide in post-abiraterone setting by Charles Bankhead , Senior Editor, MedPage Today February 23, 2021 A treatment strategy based on manipulation of testosterone levels showed promise as a potential aid for managing castration-resistant prostate cancer (CRPC), according to a randomized proof-of-principle trial. Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy (BAT) or enzalutamide (Xtan

UCSD Researchers Find More Inclusive Genetic Tool To Predict Prostate Cancer - Times of San Diego timesofsandiego.com UCSD Researchers Find More Inclusive Genetic Tool To Predict Prostate Cancer - Times of San Diego 4-5 minutes Building upon previous research, an international team led by scientists at UC San Diego School of Medicine validated a more inclusive and comprehensive genetic tool for predicting age of onset of aggressive prostate cancer, it was announced Tuesday. Reporting in Tuesday’s online edition of Nature Communications, the researchers describe the performance of a polygenic hazard score — a mathematical estimate of an individual’s age-specific genetic risk for developing a disease — in a multi-ethnic patient population. “Genetic tools to predict a man’s lifetime risk of prostate cancer might allow us to target cance

Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study - International Journal of Radiation Oncology, Biology, Physics redjournal.org Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study Search for articles by this author 4-5 minutes This paper is only available as a PDF. To read, Please Download here. Abstract Background Androgen deprivation therapy (ADT) is often used as adjuvant treatment with radiation therapy (RT) for intermediate-risk prostate cancer (PCa). ADT is associated with multiple side effects including weight gain, loss of libido and hot flashes. In contrast, anti-androgen monotherapy has been generally better tolerated. Objective Assess the effectiveness of enzalutamide (an anti-a

News of UC San Diego Health Sciences — Genetic Tool Improves Estimation of Prostate... ucsdhealthsciences.tumblr.com Genetic Tool Improves Estimation of Prostate Cancer Risk in Diverse Ethnic/Racial Groups posted 23 February, 2021 2 minutes GeneticTool Improves Estimation of Prostate Cancer Risk in Diverse Ethnic/Racial Groups Building upon previous research, an international team led by scientists at University of California San Diego School of Medicine, has validated a more inclusive and comprehensive genetic tool for predicting age of onset of aggressive prostate cancer, a disease that killed more than 33,000 American men in 2020. Reporting in the February 23, 2021 online edition of Nature Communications , the researchers describe the performance of a polygenic hazard score (PHS) — a mathematical estimate of an individuals’ age-specific genetic risk for developing a

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts - PubMed pubmed.ncbi.nlm.nih.gov Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts - PubMed Tyler M Seibert  1   2 , 17-22 minutes Comparative Study doi: 10.1136/bmj.j5757. Chun Chieh Fan   3   4 ,  Yunpeng Wang   5 ,  Verena Zuber   5   6 ,  Roshan Karunamuni   3   2